Traditional Complementary and Alternative Medicine (CAM) Therapy in the Treatment of HIV/AIDS

Condition(s) targeted: HIV Infections

Intervention: "Kallunk oxide (Immunotherapy) " (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: Traditional Alternative Medicine Research, India

Official(s) and/or principal investigator(s):
Ramakrishnan Madhusoodanan, PHD, Principal Investigator, Affiliation: Traditional Alternative Medicine Research Center

Overall contact:
Ramakrishnan Madhusoodanan, PHD, Phone: 04772270926, 9387926565, Email: tamrc_in_org@yahoo.co.in

This research work is important for the cure/control of HIV infection. The study is intended to confirm the efficacy of "Kallunk Oxide (Immunotherapy)" molecules in the Treatment of HIV infection. The study will investigate the T- Lymphocytes (immune) response to HIV in order to boost the body's natural immune ability against infection. The basic study is directly inhibit a protein's increased functions, not only in the CD4+T cell but also CD3+ and CD8+ T cells and the CD45+. cells. The 'Yogaprabhava', the drug's effectiveness, and progressive immunity with diet and lifestyle can be more easily studied.

Official title: Phase III Clinical Studies on Traditional CAM Therapy in the Treatment of HIV/AIDS

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Efficacy

Secondary outcome:

Viral Load Assay

Absolute Immune Cells Count Assay(CD3, CD4, and CD8 + T cells)

Prolonged Viral Suppression

Detailed description: This research study is an individual investigator initiated meritorious project to confirm the efficacy of "Kallunk Oxide (Immunotherapy)" in the treatment of HIV- infection. The Previous clinical studies are showing that the T- Lymphocytes responses to "Kallunk Oxide (Immunotherapy)" is effective in the treatment of HIV- infection. This randomized intervention study to confirm the efficacy of optimum dose 0. 200mg to all participants,especially, greater than 8 years old children, men and women. The Principal Investigator will be selected the informed consented patients to recruit for this trial. This study will be adhered by "Helsinki Declaration". The patient's assays of Lymphocyte Enumeration is the primary end point. Immune output of this drug and it's progressive immunity against HIV will follow- up. The study will be investigated the T- Lymphocytes (immune) response to HIV. The impact of the CD3+, CD4+,CD8 T cells and CD45+ response to "Kallunk Oxide (Immunotherapy)" will be studied. Patient's body weight, CD4+ T cells and other hematological status will be investigated before and after the treatment period. The research team is also mindful the symptoms such as nausea, fatigue and weight loss, sweating, shortness of breath, joint pain, etc. will be individually being noted. During this treatment period, in case, any of the patients have temperature, digestion complaint or chill, etc. may vary. Only in this circumstance,the patients not advised to use the controlled diet protocol or use of mutton soup, cow milk and cow ghee. Privacy and Confidentiality: The study must be handled a transparent privacy environment to recruit HIV-infected people all over India and the data will be confidentially protected with Genuine written informed consent. Dosage: 0. 200 mg "Kallunk Oxide (Immunotherapy)" molecules with the antidote 499. 800 mg "Long Pepper"(Botanical name- Piper longum) for > 8 to < 45 years old children and adults from both genders. The study will also be evaluated the effectiveness of booster dose Kallunk Oxide (5 mg) and "Long Pepper" (1995 mg) in ART drug ( one tablet contains Zidovudine, lamivudine, and nevirapine ) using adults (<45) and adolescence (the ages12 to 21 years female and 14 to 21 years old male) to access serum negative status of HIV in CD+ T cell number <350 cu/mm^3 of ART using HIV-patients.. Favorable results on integrative intervention approach is point out that before using "Kallunk Oxide (Immunotherapy)' with ART is need nearly a six hour time frame. More meaningfully, it is stated that the HIV/AIDS patient may use ART at the evening time to avoid possible side effects as joint pain and fatigue (which are seldom cases). The booster dose regimen of this therapy is administered as once daily dose for 10 days adherence with six months drug tolerance. If the virus is not suppressed completely, drug resistance can develop. So, through this study the serum negative status of HIV from baseline to 24 weeks will be followed-up. Dosage: powder form sample size product 500 mg for children and adults as once daily dose and will be recommended to 5 days daily regimen and monthly use as mentioned baseline and six (6) months time frame. Controlled Nourished diet: Patients will be controlled by nourished diet protocol. Eat wheat products, rice food products, cow milk (only ½ cup), cow ghee, green gram,banana, mutton soup,sweet fruits as apple (only sweet), orange and prepared black pepper added vegetable foods. Restriction: Salts, other oils, mustard,Pumpkin,lemon juice, and tamarind fish items are not use within 10 days of medication. Drug Administration: In this study, patients can use the capsule/powder form medicine with 1/2 cup hotter water. HIV- patients will be used one drug "Kallunk oxide (Immunotherapy)" as calcined/or oxidized molecules. Precaution: No precaution is needed. The patients can avoid sediments at the bottom of the cup.

Minimum age: 8 Years. Maximum age: 45 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Clinical diagnosis of HIV/AIDS

- Able to swallow tablets or powder form medicine

- Able to eat nutritional foods

- HIV infected patients

- Signed consent of parent or guardian for patients under 18 years of age

- Interest to use of study drugs

- Follow at a participating clinical site and

- Children greater than 8 years old.

Exclusion Criteria:

- Medical side effects

- Pregnant or breast feedings

- History of significant cardiac abnormalities or dysfunction

- Received certain drugs (Steroid) or treatments

- Unable to followed at a participating clinical center

- Children less than 8 years old

- Any serious conditions (severe chronic stage AIDS cases) at study entry that may

affect the results of the study.

- Allergy to any of the study drugs or their formulations

- Tobacco using patients

- Alcohol using patients and

- Drug addicting patients.

Ramakrishnan Madhusoodanan, PHD, Phone: 04772270926, 9387926565, Email: tamrc_in_org@yahoo.co.in

Project Site Office, Hospital of Integrated Research Site HIRS(New), Karoor, Ambalapuzha-PO, Alleppey-District, Kerala, India 688561, Alleppey 688561, India; Recruiting
Ramakrishnan Madhusoodanan, PHD, Phone: 9387926565, Email: tamrc_in_org@yahoo.co.in
Ramakrishnan Madhusoodanan, PHD, Principal Investigator

Project Site Office, Hospital of Integrated Research Site HIRS(New), Ahammed Nagar, Mathura Nagar, Bhingar- PO, Mumbai 414002, India; Recruiting
Ramakrishnan Madhusoodanan, PHD, Phone: 0091 9387926565, Email: madhusoodanan_ramakrishnan@yahoo.com
Ramakrishnan Madhusoodanan, Principal Investigator

Project Site Office, Near Sivan Kovil, Nallepily, Hospital of Integrated Research Site HIRS [new]), Palakkad, Kerala 678553, India; Active, not recruiting

Starting date: March 2012
Last updated: June 27, 2015